The University of Chicago Header Logo

Connection

Mark J. Ratain to Maximum Tolerated Dose

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Maximum Tolerated Dose.
Mark J. Ratain
Connection Strength
3.204
Maximum Tolerated Dose
  1. Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349.
    View in: PubMed
    Score: 0.864
  2. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? J Clin Oncol. 2021 11 01; 39(31):3423-3426.
    View in: PubMed
    Score: 0.738
  3. Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials. Clin Cancer Res. 2016 Feb 01; 22(3):527-9.
    View in: PubMed
    Score: 0.489
  4. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
    View in: PubMed
    Score: 0.089
  5. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10.
    View in: PubMed
    Score: 0.086
  6. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
    View in: PubMed
    Score: 0.077
  7. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92.
    View in: PubMed
    Score: 0.074
  8. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20; 25(21):3055-60.
    View in: PubMed
    Score: 0.069
  9. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1):31-7.
    View in: PubMed
    Score: 0.058
  10. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov; 22(4):449-58.
    View in: PubMed
    Score: 0.057
  11. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 01; 10(21):7244-51.
    View in: PubMed
    Score: 0.057
  12. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8.
    View in: PubMed
    Score: 0.056
  13. Finding the right dose. Clin Adv Hematol Oncol. 2003 Sep; 1(9):517-8, 531.
    View in: PubMed
    Score: 0.053
  14. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. Med Oncol. 2003; 20(1):7-12.
    View in: PubMed
    Score: 0.050
  15. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
    View in: PubMed
    Score: 0.048
  16. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs. 2022 08; 40(4):762-772.
    View in: PubMed
    Score: 0.048
  17. Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours. Br J Cancer. 2002 Feb 12; 86(4):534-9.
    View in: PubMed
    Score: 0.047
  18. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90.
    View in: PubMed
    Score: 0.045
  19. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050.
    View in: PubMed
    Score: 0.036
  20. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
    View in: PubMed
    Score: 0.029
  21. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75.
    View in: PubMed
    Score: 0.027
  22. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
    View in: PubMed
    Score: 0.023
  23. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol. 2009 Apr; 63(5):793-8.
    View in: PubMed
    Score: 0.019
  24. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
    View in: PubMed
    Score: 0.018
  25. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
    View in: PubMed
    Score: 0.018
  26. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
    View in: PubMed
    Score: 0.014
  27. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.